ProSeek Bio key facts
as of Oct 2026- Developer of biomarker-based in vitro diagnostics intended to improve detection of ovarian cancer and other women's health conditions.
- ProSeek Bio is valued at approximately $3.9M as of Oct 2026 (last reported valuation).
- It has raised $1.1M; the latest was Seed Round ($1.1M) in Mar 2026.
- Notable investors include CSIRO ON Accelerate, Edale Capital, AngelLoop, AusHealth, Medtech Global — 6 tracked in total.
- Status: Privately Held (backing).
ProSeek Bio's last reported valuation, Mar 2026. Nothing priced has surfaced since.
- ·Watch ProSeek Bio: the Monday email on marks, rounds and moves
ProSeek Bio funding rounds
No funding rounds for ProSeek Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Who backs ProSeek Bio
6ProSeek Bio valuation
ProSeek Bio's last reported valuation was $3.9 million in Mar 2026. No priced round, secondary trade or fund mark has surfaced since.
ProSeek Bio investors
6 investors are on record for ProSeek Bio, including CSIRO ON Accelerate, Edale Capital, AngelLoop and AusHealth.
About ProSeek Bio
Developer of biomarker-based in vitro diagnostics intended to improve detection of ovarian cancer and other women's health conditions. The company offers a proprietary glycoproteomics mass spectrometry platform for discovering, validating, and measuring multiple glycoform markers without antibodies, enabling healthcare providers to make earlier and more accurate diagnoses of diseases.
- Sector
- Healthcare
- HQ
- Brisbane, Australia
- Founded
- 2023
- Employees
- 10
- Website
- proseek.bio/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.